{Reference Type}: Journal Article
{Title}: Safety and Technical Efficacy of Pediatric Brainstem Biopsies: An Updated Meta-Analysis of 1000+ Children.
{Author}: Sheikh SR;Patel NJ;Recinos VM;
{Journal}: World Neurosurg
{Volume}: 0
{Issue}: 0
{Year}: 2024 Jul 3
{Factor}: 2.21
{DOI}: 10.1016/j.wneu.2024.06.163
{Abstract}: <B>BACKGROUND: </B>Brainstem tumors represent ∼10% of pediatric brain tumors, ∼80% of these are diffuse midline glioma (DMG). Given invariably poor prognosis in DMG, there continues to be immense variation worldwide in performing biopsy of these lesions. Several contemporary studies in recent years have provided new data to elucidate the safety profile of biopsy and an updated meta-analysis is thus indicated.<BR><B>METHODS: </B>We found 29 studies of pediatric brainstem biopsy in the last 20 years (2003-2023, 1002 children). We applied meta-analysis of proportions using a random-effects model to generate point estimates, confidence intervals, and measures of heterogeneity.<BR><B>RESULTS: </B>87% of procedures were stereotactic needle biopsies (of these, 62% with a frame, 14% without frame, and 24% robotic.) Biopsy resulted in a histological diagnosis ("technical yield") in 96.8% of cases (95% CI 95.4-98.2). Temporary complications were seen in 6% (95 CI 4-8), with the most common neurological complications being 1) cranial nerve dysfunction, 2) worsening or new ataxia, and 3) limb weakness. Permanent complications (excluding death) were seen in 1% (95% CI 0.5-2), most commonly including cranial nerve dysfunction and limb weakness. 5 deaths were reported in the entire pooled cohort of 1002 children (0.5%).<BR><B>CONCLUSIONS: </B>When counseling families on the merits of brainstem biopsy in children, it is reasonable to state that permanent morbidity is rare (<2%). If biopsy is performed specifically to facilitate enrollment in clinical trials requiring a molecular diagnosis, the risks of biopsy outlined here should be weighed against potential benefits of trial enrollment.